

May 31, 2022

Inopro Inc Alain Lefebvre President 800 rue Sud Porte A Cowansville, Quebec J2K 2Y3 Canada

Re: K210987

Trade/Device Name: IRRIGO Wound Wash Jet System

Regulatory Class: Unclassified Product Code: FRO, FQH Dated: March 10, 2021 Received: April 1, 2021

#### Dear Alain Lefebyre:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

K210987 - Alain Lefebvre Page 2

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">https://www.fda.gov/medical-device-problems</a>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>) and CDRH Learn (<a href="https://www.fda.gov/training-and-continuing-education/cdrh-learn">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</a>) for more information or contact DICE by email (<a href="DICE@fda.hhs.gov">DICE@fda.hhs.gov</a>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Julie Morabito, Ph.D.
Acting Assistant Director
DHT4B: Division of Infection Control
and Plastic Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

2

# DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2023 See PRA Statement below.

510(k) Number <i>(if known)</i>	
K210987	
Device Name IRRIGO Wound Wash Jet System	
Indications for Use (Describe) IRRIGO Wound Wash Jet System is intended for use by or und moistening and lubricating absorbent wound dressings, cleansing traumatic wounds such as pressure sores, leg ulcers of diabetic	ng, and maintaining a moist wound environment for
Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARA	TE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

## **Section 5: 510(k) Summary [K210987]**

### I. Regulatory Sponsor

Inopro, Inc. 800 rue Sud Porte A

Cowansville Quebec J2K 2Y3 Canada

Contact: Alain Lefebvre

Title: President

Phone: (514) 438-8481

Email: alefebvre@inopro.ca

#### II. Date Prepared

March 2, 2022

## III. Type of 510(k) Submission

Traditional

#### **IV.** Device Identification

Trade/Proprietary Name: IRRIGO Wound Wash Jet System

Common Name: Dressing, Wound, Drug

Classification: Unclassified FDA Product Code: FRO, FQH Review Panel: General Hospital

V. Legally Marketed Predicate Device(s)

#### **Primary Predicate**

K090848 Premier Saline Wound Wash

#### **Secondary Predicate**

K082330 Primary Care Solutions Sterile Water and Sterile Saline

These predicates have not been subject to a design-related recall.

## VI. Device Description

IRRIGO Wound Wash Jet System is a sterile single patient use jet lavage medical device that consists of 0.9% USP Sodium Chloride solubilized in USP Purified Water for Irrigation and packaged in a food grade compressible translucent LDPE 2oz (60mL) bottle with a LPDE luer-lock type tip spray insert and an HPDE colored cap.

The mechanism of action of the solution moving across the wound aids in the removal of foreign material, such as dirt and debris, as well as any necrotic tissue, wound exudates, and other extraneous matter. IRRIGO Wound Wash Jet System can generate upto 15 psi of stream pressure.

No preservatives are added since the finished device is sterilized by gamma irradiation.

#### VII. Indications for Use

IRRIGO Wound Wash Jet System is intended for use by or under the direction of a professional healthcare provider in moistening and lubricating absorbent wound dressings, cleansing, and maintaining a moist wound environment for traumatic wounds such as pressure sores, leg ulcers of diabetic and vascular origin, cuts, abrasions, and minor burns.

For Prescription Use Only.

## VIII. Substantial Equivalence Comparison Table

Device Name	IRRIGO Wound	Premier Sterile	Primary Care	Substantial
	Wash Jet System	Saline Wound	Solutions Sterile	Equivalent
	-	Wash	Water and Sterile	(SE)
			Saline	
	Subject Device	Primary Predicate	Secondary	
	, and the second	·	Predicate	
510(k) #	K210987	K090848	K082330	
CI • • • • • •	EDO FOIL	EDO EON	EDO EOU IOI	
Classification	FRO, FQH	FRO, FQH	FRO, FQH, JOL	SE
Product				
Code	0.00/ 1' 11 '1	0.00/ 1	0.00/ 1	CIE
Fluid	0.9% sodium chloride	0.9% sodium	0.9% sodium	SE
Composition	(USP) and purified	chloride (USP) and	chloride (USP) and	
	water (USP)	purified water (USP)	sterile water for	
T 11 .4		7	irrigation (USP)	GT G 11
Indications	Rx:	Rx:	Rx:	SE; Subject
For Use	IRRIGO Wound	Saline Wound Wash	Moisturizing of	device -
	Wash Jet System is	is intended for use by	Wound Dressings,	Irrigo is for
	intended for use by or	or under the direction	Device Irrigation	Rx Only.
	under the direction of	of a professional	and Jet Lavage for	
	professional	healthcare provider	Tissue Debridement	
	healthcare provider in	in moistening and		
	moistening and	lubricating absorbent		
	lubricating absorbent	wound dressings,		
	wound dressings,	cleansing, and		
	cleansing, and	maintaining a moist		
	maintaining a moist	wound environment		
	wound environment	for traumatic wounds		
	for traumatic wounds	such as pressure		
	such as pressure	sores, leg ulcers of		
	sores, leg ulcers of	diabetic and vascular		
	diabetic and vascular	origin, cuts,		



IRRIGO

Oro 💙 inc.				
O Wound Was			Trac	litional 510(k)
	origin, cuts, abrasions, and minor burns.	abrasions, and minor burns.		
		OTC: Saline Wound Wash is intended for use in moistening and lubricating absorbent wound dressings and for cleansing minor wounds, scrapes and minor burns. If redness, swelling or bleeding continues, please seek the help of nurse, nurses aid, doctor, or other medical professional.		
Description	IRRIGO Wound Wash Jet System is a sterile single patient use jet lavage medical device that consists of 0.9% USP Sodium Chloride solubilized in USP Purified Water for Irrigation and packaged in a food grade compressible translucent LDPE 2oz (60mL) bottle with a LPDE luer-lock type tip spray insert and an HPDE colored cap.	Saline Wound Wash is a multi-use, isotonic, sterile saline solution packaged in a bag-incan aerosol system.  Actuation of the device (product can) delivers a consistent flow of sterile isotonic saline solution at published safe and effective wound impact pressures of 4 to 15 psi (Clinical Practice Guideline Number 15 AHCPR, US Health and Human Services).	This device is USP purified water or saline sealed in 100mL HDPE bottles or 120mL HIPS cups.	SE; Subject device - Irrigo is similar to both predicates. Difference is Primary Predicate is a bag-in-can aerosol system; Subject device is in a non-aerosol bottle.  Subject and primary predicate capable of delivering upto 15 psi of pressure; Unknown for Secondary Predicate.



## IRRIGO Wound Wash Jet System

Mechanism of Action	The mechanical action of isotonic saline solution moving across the wound aids in the removal of foreign material, such as dirt and debris, as well as any necrotic tissue, wound exudates and other extraneous matter.	The mechanical action of isotonic saline solution moving across the wound aids in the removal of foreign material, such as dirt and debris, as well as any necrotic tissue, wound exudates and other extraneous matter.	The mechanical action of isotonic saline solution moving across the wound aids in the removal of foreign material, such as dirt and debris, as well as any necrotic tissue, wound exudates and other extraneous matter.	SE
Preservative	No preservatives are added since the finished device is sterilized by gamma irradiation.	No preservatives are added since the finished device is sterilized by gamma irradiation.	Unknown	SE; Subject and Primary Predicate; Unknown for Secondary Predicate
Packaging	IRRIGO Wound Wash Jet System is a sterile single patient use jet lavage medical device that consists of 0.9% USP Sodium Chloride solubilized in USP Purified Water for Irrigation and packaged in a food grade compressible translucent LDPE 2oz (60mL) bottle with a LPDE luer-lock type tip spray insert and an HPDE colored cap.	Saline Wound Wash is an aerosol bag-incan system.  The propellant, compressed air, is charged into the container between the bag and the can creating a means to dispense the contents of the bag, isotonic sterile saline solution.  The bag is a 4-layer laminate system including a sandwiched polyethylene layer establishing an impermeable barrier between the propellant (compressed air) and the bag contents (sterile isotonic saline).  The isotonic saline solution of is in contact with either a	100mL HDPE bottles or 120mL HIPS cups	SE; Subject and Secondary Predicate similar, Primary predicate – aerosol bag- in-can system

IRRIGO Wound Wash Jet System

Traditional	51	$\Omega$	(k)
Traumona	91	v	N

				\ /
		0.9% sodium		
		chloride solution		
		prepared from		
		sodium chloride,		
		USP, and purified		
		water, USP.		
Sterilization	Gamma	Gamma	Gamma	SE
Method				
Single	Single Use	Multi Use	Single Use	SE; Subject
Use/Multi-				Device is for
Use				Single Use
				Only.
Rx or OTC	Rx	Both	Rx	SE; Subject
				Device is for
				Rx Use Only.

## IX. Summary of Bench Testing

IRRIGO Wound Wash is tested against the following established specifications and standards:

- USP 43-NF38:2020 Sodium Chloride Irrigation
- USP 43-NF38:2020 <71> Sterility Tests
- USP 43-NF38:2020 <85> Bacterial Endotoxins Test
- USP 43-NF38:2020 Purified Water
- USP 43<541> Titrimetry Sodium Chloride Assay
- ANSI AAMI ISO 11137-1 Sterilization of healthcare products -Radiation Part 1 Requirements for development, validation, and routine control of a sterilization process for medical devices
- ANSI AAMI ISO 11137-2 Sterilization of healthcare products -Radiation Part 2 Establishing the sterilization dose.
- ANSI AAMI ST67:2019 Sterilization of healthcare products Requirements and guidance for selecting a sterility assurance level (SAL)
- IRRIGO PSI Testing/Internal Pressure Curves
- Packaging integrity leak test

IRRIGO Wound Wash Jet System is tested against established specifications and meets Biocompatibility requirements:

- ISO 10993-5 Cytotoxicity
- ISO 10993-10 Intracutaneous Reactivity
- ISO 10993-10 Skin Sensitization
- ISO 10993-11 Acute Systemic Toxicity
- <USP 151> Material-Mediated Pyrogenicity

## X. Statement of Substantial Equivalence

The subject device and predicate devices are jet lavage devices used to clean a wound by a pulsatile jet of sterile fluid. These devices have the same intended use and similar technological characteristics. IRRIGO Wound Wash Jet System has the same intended use and indications for use as the primary and secondary predicate devices. Any minor differences in the technological features of the subject device when compared to the predicate devices have been evaluated through safety and performance testing and other verification and validation testing activities such that the information demonstrates that the subject device, when compared to the predicted devices, does not raise any new questions of safety and effectiveness. IRRIGO Wound Wash Jet System has been determined to be substantially equivalent to the predicate devices.